The relationship between Microsoft (NASDAQ: MSFT) and OpenAI just got a lot more complicated — and for investors watching the enterprise software and AI space, the implications stretch well beyond two companies renegotiating a contract.
On Monday, Microsoft announced a sweeping revision to its long-term partnership with OpenAI, officially ending its exclusive access to the AI startup’s intellectual property and models. Under the original agreement, Microsoft held exclusive rights to OpenAI’s IP and technology until the company achieved artificial general intelligence (AGI) — a milestone defined as AI that matches or surpasses human intelligence. That clause is now gone.
The revised deal allows OpenAI to distribute its models through any cloud provider, including direct competitors like Amazon Web Services. Microsoft’s Azure platform retains its designation as OpenAI’s primary cloud infrastructure and will continue to receive first access to new OpenAI products — but the competitive moat that defined the original partnership has been significantly narrowed. In exchange, Microsoft will no longer make revenue-sharing payments to OpenAI, though OpenAI is still obligated to continue paying revenue share back to Microsoft through 2030.
MSFT shares dipped roughly 1% on the announcement.
The timing is notable. The renegotiation comes just two days before Microsoft reports quarterly earnings on Wednesday — an earnings report already under a microscope after a rough six months for the stock. MSFT has lost approximately 20% over that period, while cloud rivals Amazon (NASDAQ: AMZN) and Google parent Alphabet (NASDAQ: GOOG) have surged 17% and 30%, respectively.
A key metric investors will be watching Wednesday is Azure’s growth rate. In its last reported quarter, Microsoft disclosed that Azure revenue growth was constrained by data center capacity — the business grew 38%, but management indicated it would have hit 40% with sufficient infrastructure in place. Any update on capacity buildout and AI-driven cloud demand will likely move the stock.
But the bigger story here may not be Microsoft at all — it’s what this deal signals for the broader enterprise software market. The so-called “SaaS-pocalypse” — the fear that AI labs like OpenAI and Anthropic will build their own enterprise tools and disintermediate traditional software providers — has been quietly hammering the sector for months. With OpenAI now free to go directly to any cloud customer through any platform, that risk just became more tangible.
The damage is already showing up in valuations. Salesforce (NYSE: CRM) and ServiceNow (NYSE: NOW) are each down roughly 31% year-to-date. Thomson Reuters (NYSE: TRI) has shed more than 40%. These are not small-cap companies, but the ripple effects are being felt across the entire software ecosystem — including the mid-market and smaller players who compete for enterprise IT budgets.
For the small and microcap space, the takeaway is straightforward: the enterprise software stack is being repriced in real time. Companies that built their value proposition around integrating with or complementing legacy SaaS platforms need to be asking hard questions about their positioning as AI-native competitors gain distribution.
The Microsoft-OpenAI relationship has always been one of the most consequential partnerships in tech. Monday’s announcement makes it clear that even that relationship isn’t immune to the disruption reshaping the entire industry.
Eli Lilly (NYSE: LLY) announced today it has entered into a definitive agreement to acquire Ajax Therapeutics, a private biopharmaceutical company developing next-generation JAK inhibitors for patients with myeloproliferative neoplasms (MPNs) — a group of blood cancers that includes myelofibrosis and polycythemia vera. Under the terms of the deal, Ajax shareholders could receive up to $2.3 billion in cash, comprising an upfront payment and additional milestone-based payments tied to clinical and regulatory progress.
The centerpiece of the acquisition is AJ1-11095, an investigational, once-daily oral drug that represents the first-in-class Type II JAK2 inhibitor currently in Phase 1 clinical development. That distinction matters. Every JAK2 inhibitor currently approved for MPNs — including market standards like ruxolitinib — targets the Type I conformation of JAK2. While these treatments offer symptomatic relief, a significant portion of patients eventually lose response or discontinue therapy altogether due to diminishing efficacy.
AJ1-11095 was specifically engineered to address that gap. By binding JAK2 in its inactive Type II conformation, the compound is designed to deliver deeper and more durable disease control — and potentially serve patients who have already failed on existing Type I therapies. Phase 1 dosing began in late 2024, with dose selection for future development expected later this year. First proof-of-concept clinical data is also expected to be presented in 2026.
For Lilly, this isn’t a cold acquisition. The pharma giant was a founding strategic investor in Ajax, meaning today’s deal is less a discovery and more a conviction play — Lilly has seen the science up close and is now moving to own it outright. The transaction builds on Lilly’s established blood cancer capabilities and continues what has been an aggressive dealmaking year for the Indianapolis-based company. Lilly has already announced the acquisitions of Ventyx Biosciences for $1.2 billion and Orna Therapeutics for up to $2.4 billion earlier in 2026.
Lilly’s activity isn’t an outlier — it’s a signal of where the broader market is heading. Biopharma M&A totaled $15.6 billion across 19 deals in Q1 2026 alone, a pace that reflects the structural pressure Big Pharma is operating under. An estimated $236 billion in annual revenue is at risk across the industry from patent expirations of blockbuster drugs, forcing companies to look externally for pipeline replenishment.
Emerging biopharma companies now represent 70% of all clinical-stage assets, with a significant portion remaining unpartnered — and with the IPO market yet to fully recover, many smaller biotech firms are pursuing M&A or partnerships as the most viable path forward. That dynamic creates a fertile hunting ground for acquirers with balance sheet firepower and strategic focus.
The Ajax deal is a textbook example of what is driving this wave: a differentiated mechanism, a validated scientific rationale, an unmet patient need, and a buyer that already understands the asset. For investors watching the small and micro-cap biotech space, the pattern is worth tracking. Companies developing first-in-class mechanisms in high-need therapeutic areas — particularly in oncology and hematology — are drawing premium attention from large-cap acquirers willing to pay up before Phase 3 data is in hand.
The transaction remains subject to customary closing conditions, including Hart-Scott-Rodino antitrust clearance.
PURCHASE, N.Y., April 27, 2026 (GLOBE NEWSWIRE) — Townsquare Media, Inc. (NYSE: TSQ) (“Townsquare” or the “Company”), a leader in digital advertising and marketing solutions focused on markets outside of the Top 50 in the United States, announced today a strategic digital advertising partnership with North American Broadcasting Company (“NABCO”). NABCO is a locally-owned radio broadcast company based in Columbus, Ohio, a Top 50 DMA.
“Our partnership with North American Broadcast Company extends our ability to bring market-leading digital advertising solutions to a broader set of local media operators operating in large markets,” said Shaun Collignon, CRO of Townsquare Ignite, the Company’s Digital Advertising division. “Our success is driven by deep expertise in leveraging our proprietary programmatic platform and data-driven strategies to deliver measurable results. We look forward to equipping NABCO with the tools, insights, and proven strategic approach needed to accelerate their digital growth and drive meaningful outcomes for their clients.”
“We are extremely happy to partner with Townsquare’s Ignite platform. It delivers robust capacity to efficiently plan, execute and monitor complex digital solutions. We believe the platform and its people provide our team industry-leading, data-driven capability that we are thrilled to bring to our customers,” said Matt Mnich, President and CEO NABCO. “The technology and expertise upon which Ignite is built are impressive. It wholistically delivers the solution we were seeking.”
Townsquare announced the launch of the Media Partnerships division in 2024, as part of its Digital Advertising segment, Townsquare Ignite. The division offers a white-label solution that enables local media companies to leverage the same digital advertising capabilities that have driven Townsquare’s growth, with digital now accounting for more than 50% of the Company’s total revenue and profit.
The alliance with NABCO is one of 11 partnerships Townsquare has recently established under this initiative, collectively expanding its reach into 31 incremental markets that do not overlap with its existing footprint. Through this partnership, Townsquare will bring its expertise, technology, and resources to NABCO, delivering customized, data-driven strategies tailored to the needs of local, regional, and national advertisers, while supporting the continued growth of NABCO’s digital business alongside its established broadcast platform.
About Townsquare Media, Inc.
Townsquare is a community-focused digital and broadcast media and digital marketing solutions company principally focused outside the top 50 markets in the U.S.Townsquare Ignite, our robust digital advertising division, specializes in helping businesses of all sizes connect with their target audience through data-driven, results based strategies, by utilizing a) our proprietary digital programmatic advertising technology stack with an in-house demand and data management platform and b) our owned and operated portfolio of more than 400 local news and entertainment websites and mobile apps along with a network of leading national music and entertainment brands, collecting valuable first party data. Townsquare Interactive, our subscription digital marketing services business, partners with SMBs to help manage their digital presence by providing a SAAS business management platform, website design, creation and hosting, search engine optimization and other digital services. And through our portfolio of local radio stations strategically situated outside the Top 50 markets in the United States, we provide effective advertising solutions for our clients and relevant local content for our audiences. For more information, please visit www.townsquaremedia.com, www.townsquareinteractive.com, and www.townsquareignite.com.
About NABCO
North American Broadcasting Company, Inc. is a locally owned Central Ohio company established in 1957, delivering four diverse radio stations in the market, all targeting a different demographic. WRKZ (99.7 The Blitz), is Active/Mainstream Rock, WJKR-FM (The Maverick) is Classic Hit Country station, WMNI-AM 920 (Fox Sports Radio Columbus) is an all sports stations featuring Colin Cowherd, Dan Patrick, Columbus Clippers and more! WJKR-HD2 on 94.1FM (Star 94.1) is a lite favorites station featuring lite hits from 80s, 90s and now.
Positioned to Enhance Efficacy of Checkpoint Inhibitors and Next-Generation Oncology Modalities Across Solid Tumors
ATLANTA, GA – April 27, 2026 – GeoVax Labs, Inc. (Nasdaq: GOVX), a clinical-stage biotechnology company developing immunotherapies and vaccines against cancers and infectious diseases, today highlighted the strategic positioning of its oncology asset, Gedeptin® (Ad/PNP), in the context of accelerating industry investment in next-generation in vivo cancer therapies.
Recent high-profile transactions and investments across the biopharmaceutical sector underscore a growing focus on therapies designed to simplify delivery, improve scalability, and expanding therapeutic reach. As these approaches advance, a central challenge remains: many tumors are immunologically “cold,” limiting the effectiveness of even the most advanced therapeutic modalities. GeoVax believes Gedeptin is uniquely positioned to address this challenge.
“While the industry is investing heavily in next-generation cell and gene therapies, the ability to positively modify the local tumor environment is believed to be one of the critical determinants of clinical success,” said David A. Dodd, Chairman and Chief Executive Officer of GeoVax. “Gedeptin is designed to directly destroy both proliferating and non-proliferating tumors, while also demonstrating high bystander activity due to the ability of the in situ generated cytotoxic agent ability to diffuse into neighboring tumor cells.”
Gedeptin is a gene-directed enzyme prodrug therapy (GDEPT), delivered intratumorally, designed to generate PNP, selectively destroy both proliferating and non-proliferating tumor cells within the treated tumor. In vivo preclinical experiments have shown PNP treatment to be additive or synergistic with checkpoint blockade–type agents. For example, studies in preclinical in vivo tumor models of metastasis, have demonstrated treatment of a single lesion can robustly sensitize tumors to checkpoint blockade inhibitors, presumably by destroying tumor tissue (including the tumor microenvironment), exposing neoantigens, and enhancing immune response and activity of immune check point inhibitors (ICIs) at distant PNP-untreated lesions This dual mechanism – localized cytotoxicity combined with enhancing the immune response and activity of immune check point inhibitors against both Gedeptin treated and untreated tumors – has the potential to offer an improved therapeutic approach to addressing solid tumor metastatic disease.
GeoVax has generated preclinical, clinical and translational data supporting Gedeptin’s ability to:
Induce localized tumor cell death against both proliferating and non-proliferating tumors, while minimizing systemic toxicity
Potentially improve response rates when combined with immune checkpoint inhibitors
Aligned with the Next Phase of Immuno-Oncology Innovation
As checkpoint inhibitors continue to move earlier in treatment paradigms, including neoadjuvant and first-line settings, the need for complementary approaches that enhance response rates is becoming increasingly evident.
GeoVax is advancing Gedeptin in combination with checkpoint inhibition in a planned Phase 2 clinical trial in first-line head and neck cancer therapy, with additional solid tumor indications under evaluation.
“Checkpoint inhibitors have transformed cancer care, but many patients still do not achieve durable responses,” said Kelly T. McKee, M.D., Chief Medical Officer of GeoVax. “We believe Gedeptin is well positioned as a combination-enabling platform designed to enhance therapeutic response across checkpoint inhibitors and other emerging oncology modalities.”
About Gedeptin®
Gedeptin® is a gene-directed enzyme prodrug therapy (GDEPT) delivered intratumorally using a non-replicating viral vector encoding purine nucleoside phosphorylase (PNP). Following administration of a systemically delivered prodrug, the encoded enzyme converts the prodrug into a cytotoxic agent directly within the tumor microenvironment. This localized approach is designed to selectively destroy tumor cells while promoting immune recognition and minimizing systemic toxicity. Gedeptin has received Orphan Drug Designation for oral and pharyngeal cancers.
The Company continues to evaluate strategic partnerships and collaborations to advance the clinical development and potential commercialization of Gedeptin-based combination therapies.
About GeoVax
GeoVax Labs, Inc. is a clinical-stage biotechnology company focused on the development of vaccines and immunotherapies addressing high-consequence infectious diseases and solid tumor cancers. GeoVax’s priority program is GEO-MVA, a Modified Vaccinia Ankara (MVA)–based vaccine targeting mpox and smallpox. The program is advancing under an expedited regulatory pathway, with plans to initiate a pivotal Phase 3 clinical trial in the second half of 2026, to address critical global needs for expanded orthopoxvirus vaccine supply and biodefense preparedness. In oncology, GeoVax is developing Gedeptin®, a gene-directed enzyme prodrug therapy (GDEPT) designed to enhance immune checkpoint inhibitor activity. Gedeptin has completed a multicenter Phase 1/2 clinical trial in advanced head and neck cancer and is being advanced into combination strategies, including planned neoadjuvant and first-line settings. GeoVax’s broader pipeline includes the development of GEO-CM04S1, a next-generation COVID-19 vaccine candidate being evaluated in immunocompromised and other patient populations. GeoVax maintains a global intellectual property portfolio supporting its infectious disease and oncology programs and continues to evaluate strategic partnerships and funding opportunities aligned with its development priorities. For more information, visit www.geovax.com.
Forward-Looking Statements
This release contains forward-looking statements regarding GeoVax’s business plans. The words “believe,” “look forward to,” “may,” “estimate,” “continue,” “anticipate,” “intend,” “should,” “plan,” “could,” “target,” “potential,” “is likely,” “will,” “expect” and similar expressions, as they relate to us, are intended to identify forward-looking statements. We have based these forward-looking statements largely on our current expectations and projections about future events and financial trends that we believe may affect our financial condition, results of operations, business strategy and financial needs. Actual results may differ materially from those included in these statements due to a variety of factors, including whether: GeoVax is able to obtain acceptable results from ongoing or future clinical trials of its investigational products, GeoVax’s immuno-oncology products and preventative vaccines can provoke the desired responses, and those products or vaccines can be used effectively, GeoVax’s viral vector technology adequately amplifies immune responses to cancer antigens, GeoVax can develop and manufacture its immuno-oncology products and preventative vaccines with the desired characteristics in a timely manner, GeoVax’s immuno-oncology products and preventative vaccines will be safe for human use, GeoVax’s vaccines will effectively prevent targeted infections in humans, GeoVax’s immuno-oncology products and preventative vaccines will receive regulatory approvals necessary to be licensed and marketed, GeoVax raises required capital to complete development, there is development of competitive products that may be more effective or easier to use than GeoVax’s products, GeoVax will be able to enter into favorable manufacturing and distribution agreements, and other factors, over which GeoVax has no control.
Further information on our risk factors is contained in our periodic reports on Form 10-Q and Form 10-K that we have filed and will file with the SEC. Any forward-looking statement made by us herein speaks only as of the date on which it is made. Factors or events that could cause our actual results to differ may emerge from time to time, and it is not possible for us to predict all of them. We undertake no obligation to publicly update any forward-looking statement, whether as a result of new information, future developments or otherwise, except as may be required by law.
NEW YORK, April 27, 2026 (GLOBE NEWSWIRE) — Xcel Brands (NASDAQ: XELB), An industry-leading media and consumer products company focused on building influencer-driven brands through social commerce and live streaming is proud to announce that Latina superstar chef Jenny Martinez will debut her Mesa Mia by Jenny Martinez kitchen collection on HSN (The Home Shopping Network). The brand will showcase home-inspired kitchenware and authentic Latina cuisine and will be available to consumers on HSN starting April 28, 2026.
“We are excited for Jenny to introduce Mesa Mia by Jenny Martinez to the HSN customer through livestream TV and invite her enormous social following to join her on this new journey. Jenny’s warm personality, playful sense of humor and love of her Latin heritage that she expresses through her delicious recipes, many from her childhood make for engaging and fun filled television,” stated Robert W. D’Loren, Chairman and Chief Executive Officer of Xcel Brands.
Rooted in the belief that food connects, inspires, and creates lasting memories, Jenny’s kitchen collection and ready-to-enjoy meals draw inspiration from her Mexican heritage and upbringing in Chapala, Jalisco. Her collection brings the warmth of tradition into every home, one bite at a time.
“Jenny’s fans connect to her stories in a personal way that’s really so moving to see,” said John Frierson, President of talent agency The Bureau New York City. “And as a result, Jenny has been able to transition from influencer to lifestyle icon.”
“Growing up, the kitchen was always the heart of our home, it’s where stories were shared, traditions were created, and love was felt in every dish. To me, Mesa Mia means more than just “my table” – its is about creating a space where everyone fells welcome. With this collection, I wanted to being the same sense of connection and warmth to every table, inviting people to gather, celebrate food, and make lasting memories together,” said Jenny Martinez “I’ve always wanted to put a kitchen collection, authentic food and rich storytelling together in one place, and Xcel Brands helped me to bring that dream to life.”
About Xcel Brands
Xcel Brands, Inc. (NASDAQ: XELB) is a media and consumer products company engaged in the design, licensing, marketing, live streaming, and social commerce sales of branded apparel, footwear, accessories, fine jewelry, home goods and other consumer products, and the acquisition of dynamic consumer lifestyle brands. Xcel was founded in 2011 with a vision to reimagine shopping, entertainment, and social media as social commerce. Xcel owns the Halston, Judith Ripka, and C. Wonder brands, as well as the co-branded collaboration brands TowerHill by Christie Brinkley, Trust. Respect. Love by Cesar Millan, GemmaMade by Gemma Stafford and Off/Duty by Coco Rocha brand and also holds noncontrolling interests or long-term license agreement in MesaMia by Jenny Martinez. Xcel also owns and manages the Longaberger by Shannon Doherty brand through its controlling interest in Longaberger Licensing, LLC. Xcel is pioneering a modern consumer products sales strategy which includes the promotion and sale of products under its brands through interactive television, digital live-stream shopping, social commerce, brick-and-mortar retailers, and e-commerce channels to be everywhere its customer’s shop. The company’s previously owned and current brands have generated in excess of $5 billion in retail sales via livestreaming in interactive television and digital channels alone, and has over 20,000 hours of content production time in live-stream and social commerce. The brand portfolio reaches in excess of 46 million social media followers with broadcast reach into 200 million households. Headquartered in New York City, Xcel Brands is led by an executive team with significant live streaming, production, merchandising, design, marketing, retailing, and licensing experience, and a proven track record of success in elevating branded consumer products companies. For more information, visit www.xcelbrands.com.
About Jenny Martinez Jenny Martinez is well-known across social media platforms for sharing her authentic Mexican family recipes to the delight of millions of fans on TikTok and Instagram. Jenny was born in Mexico and moved to Los Angeles at age four, yet she has never lost touch with her Mexican heritage. The traditional recipes she shares with her followers have been passed down for generations in her family. Although she later mastered her culinary arts on her own, Jenny started by learning most of her mother’s recipes at the age of thirteen. Jenny considers a well-fed family the key to a happy family and believes that dinner should be celebrated every day. Food brings people together, and Jenny’s videos and recipes convey the spirit of family and community. She lives with her family in Los Angeles, California. Jenny’s first cookbook My Mexican Mesa, Y Listo! (Simon & Schuster) debuted in Spring 2024 featuring 100 recipes ranging from breakfast, appetizers & entrees to desserts, and even cocktails! Providing family-style recipes for every occasion & beautifully photographed to capture the authentic spirit of the cuisine, the cookbook is a must-have for home cooks looking for their next delicious meal. In 2024, Jenny launched her own line of cookware and dinnerware/tabletop at over 600 department stores nationally, as well as a spice line sold in grocery stores and online.
Jenny is represented by John Frierson at The Bureau New York City and managed by Lisa Shotland at Shotlandia. Her attorney is Phil Daniels at Ginsberg Daniels Kallis LLP.
Sports.com Predict to launch ahead of the 2026 FIFA World Cup, positioning SEGG Media to capitalize on the world’s largest sporting event through transaction-based fan engagement.
Platform is designed as a long-term growth engine, targeting high-margin revenue opportunities within the rapidly expanding global sports predictions market.
FORT WORTH, Texas, April 27, 2026 (GLOBE NEWSWIRE) — Sports.com Predict, the new sports predictions platform unveiled last week by Sports Entertainment Gaming Global Corporation (NASDAQ: SEGG, LTRYW) (the “Company” or “SEGG Media”), is expected to be live in advance of the 2026 FIFA World Cup.
With global attention turning to the world’s biggest sporting tournament, Sports.com Predict will offer fans a new way to engage with football’s biggest moments through predictions. Developed as a scalable digital platform, it is designed to support recurring, repeatable revenue through transaction-based commission activity around major sporting events.
The 2026 FIFA World Cup is expected to drive a surge in global fan engagement, creating a compelling opportunity to showcase the platform at scale, as hundreds of millions of fans seek new, more interactive, real-time ways to engage with the tournament.
A new holding page on Sports.com is live, allowing fans to register their interest ahead of launch and receive updates as Sports.com Predict prepares for launch ahead of the World Cup.
Marc Bircham, Chairman of SEGG Media, said:“Major global tournaments, including the World Cup, create sustained fan engagement at scale, and launching ahead of it positions us to capture and monetize that demand. Crucially, however, Sports.com Predict is being built as a long-term growth engine, designed to support scalable, high-growth, high-margin revenue streams well beyond a single event.”
As digital engagement around sport continues to evolve, prediction-based platforms are becoming an increasingly important part of the wider sports ecosystem. Sports.com Predict is positioned as a long-term growth engine within the SEGG Media network and is expected to scale across major sporting events and geographies.
The platform is being rolled out in phases, subject to regulatory considerations and development progress.
About SEGG Media Corporation
SEGG Media (Nasdaq: SEGG, LTRYW) is a global sports, entertainment, and gaming group operating a portfolio of digital assets including Sports.com, Concerts.com, TicketStub.com, Lottery.com, and Veloce Media Group. Focused on immersive fan engagement, ethical gaming, and AI-driven live experiences, SEGG Media is redefining how global audiences interact with the content they love.
Important Notice Regarding Forward-Looking Statements
This press release contains statements that constitute “forward-looking statements” within the meaning of Section 27A of the Securities Act of 1933, as amended, and Section 21E of the Securities Exchange Act of 1934, as amended. All statements, other than statements of present or historical fact included in this press release, regarding the Company’s strategy, future operations, prospects, plans and objectives of management, are forward-looking statements. When used in this Form 8-K, the words “could,” “should,” “will,” “may,” “believe,” “anticipate,” “intend,” “estimate,” “expect,” “project,” “initiatives,” “continue,” the negative of such terms and other similar expressions are intended to identify forward-looking statements, although not all forward-looking statements contain such identifying words. These forward-looking statements are based on management’s current expectations and assumptions about future events and are based on currently available information as to the outcome and timing of future events. The forward-looking statements speak only as of the date of this press release or as of the date they are made. The Company cautions you that these forward-looking statements are subject to numerous risks and uncertainties, most of which are difficult to predict and many of which are beyond the control of the Company. In addition, the Company cautions you that the forward-looking statements contained in this press release are subject to risks and uncertainties, including but not limited to, any future findings from ongoing review of the Company’s internal accounting controls, additional examination of the preliminary conclusions of such review, the Company’s ability to secure additional capital resources, the Company’s ability to continue as a going concern, the Company’s ability to respond in a timely and satisfactory matter to the inquiries by Nasdaq, the Company’s ability to regain compliance with the Bid Price Requirement, the Company’s ability to regain compliance with Nasdaq Listing Rules, the Company’s ability to become current with its SEC reports, and those additional risks and uncertainties discussed under the heading “Risk Factors” in the Form 10-K/A filed by the Company with the SEC on April 22, 2025, and the other documents filed, or to be filed, by the Company with the SEC. Additional information concerning these and other factors that may impact the operations and projections discussed herein can be found in the reports that the Company has filed and will file from time to time with the SEC. These SEC filings are available publicly on the SEC’s website at www.sec.gov. Should one or more of the risks or uncertainties described in this press release materialize or should underlying assumptions prove incorrect, actual results and plans could differ materially from those expressed in any forward-looking statements. Except as otherwise required by applicable law, the Company disclaims any duty to update any forward-looking statements, all of which are expressly qualified by the statements in this section, to reflect events or circumstances after the date of this press release.
CERRITOS, Calif., April 27, 2026 (GLOBE NEWSWIRE) — The Oncology Institute, Inc. (“TOI”) (NASDAQ: TOI) a pioneer in value-based community oncology care, today announced that the company will release its first quarter 2026 financial results on Thursday, May 7, 2026, to be followed by a conference call the same day at 5:30 p.m. (Eastern Time).
The conference call can be accessed live over the phone by dialing 1-800-225-9448 or for international callers, 1-203-518-9708. A replay will be available two hours after the call and can be accessed by dialing 1-844-512-2921, or for international callers, 1-412-317-6671. The passcode for the live call and the replay is 11161701. The replay will be available until Thursday May 21, 2026.
Interested investors and other parties may also listen to a simultaneous webcast of the conference call by logging onto the Investor Relations section of the Company’s website at https://investors.theoncologyinstitute.com/.
About The Oncology Institute
Founded in 2007, The Oncology Institute (NASDAQ: TOI) is advancing oncology by delivering highly specialized, value-based cancer care in the community setting. TOI offers cutting-edge, evidence-based cancer care to a population of approximately 1.9 million patients, including clinical trials, transfusions, and other care delivery models traditionally associated with the most advanced care delivery organizations. With over 180 employed and affiliate clinicians and over 100 clinics and affiliate locations of care across five states and growing, TOI is changing oncology for the better.
SAN DIEGO, April 27, 2026 (GLOBE NEWSWIRE) — Kratos Defense & Security Solutions, Inc. (NASDAQ: KTOS), a Technology Company in the Defense, National Security and Global Markets, announced today that it will publish financial results for the first quarter 2026 after the close of market on Wednesday, May 6th. Management will discuss the Company’s operations and financial results in a conference call beginning at 2:00 p.m. Pacific (5:00 p.m. Eastern).
The call will be available at www.kratosdefense.com. Participants may register for the call using this Online Form. Upon registration, all telephone participants will receive the dial-in number along with a unique PIN that can be used to access the call. For those who cannot access the live broadcast, a replay will be available on Kratos’ website.
About Kratos Defense & Security Solutions Kratos Defense & Security Solutions, Inc. (NASDAQ: KTOS) is a technology, products, system and software company addressing the defense, national security, and commercial markets. Kratos makes true internally funded research, development, capital and other investments, to rapidly develop, produce and field solutions that address our customers’ mission critical needs and requirements. At Kratos, affordability is a technology, and we seek to utilize proven, leading edge approaches and technology, not unproven bleeding edge approaches or technology, with Kratos’ approach designed to reduce cost, schedule and risk, enabling us to be first to market with cost effective solutions. We believe that Kratos is known as an innovative disruptive change agent in the industry, a company that is an expert in designing products and systems up front for successful rapid, large quantity, low cost future manufacturing which is a value add competitive differentiator for our large traditional prime system integrator partners and also to our government and commercial customers. Kratos intends to pursue program and contract opportunities as the prime or lead contractor when we believe that our probability of win (PWin) is high and any investment required by Kratos is within our capital resource comfort level. We intend to partner and team with a large, traditional system integrator when our assessment of PWin is greater or required investment is beyond Kratos’ comfort level. Kratos’ primary business areas include virtualized ground systems for satellites and space vehicles including software for command & control (C2) and telemetry, tracking and control (TT&C), jet powered unmanned aerial drone systems, hypersonic vehicles and rocket systems, propulsion systems for drones, missiles, loitering munitions, supersonic systems, space craft and launch systems, C5ISR and microwave electronic products for missile, radar, missile defense, space, satellite, counter UAS, directed energy, communication and other systems, and virtual & augmented reality training systems for the warfighter. For more information, visit www.KratosDefense.com
Saguenay-Lac-Saint-Jean, Québec–(Newsfile Corp. – April 27, 2026) – First Phosphate Corp. (CSE: PHOS) (OTCQX: FRSPF) (OTCQX ADR: FPHOY) (FSE: KD0) (“First Phosphate” or the “Company“) is pleased to announce analytical results for its infill drill program, completed on March 31, 2026, at its Bégin-Lamarche property in Saguenay-Lac-Saint-Jean, Québec, Canada.
As previously announced, the Company’s recent infill drilling campaign across the three major zones (Mountain, North and South) has confirmed extensive, continuous mineralization throughout the existing horizon of the initial Mineral Resource Estimate (“MRE”) as well as two new phosphate intersects.
Existing mineralized areas, as well as the two newly discovered intersects, have now been defined in all directions and at depth. Based on the current assay results, the Mineral Resources identified in the Company’s initial MRE, dated September 9, 2024, are now being updated into a current geological model which will be produced next month.
In the Mountain Zone, several intervals exceeding 50 m with grades above 10% P₂O₅ were intersected within the broader composite intervals. Several massive apatite veins reaching up to 2 m in thickness were also encountered.
The Northern Zone highlights the discovery of high-grade phosphate occurring in down-dip continuity. These high grades share mineralogical and visual characteristics (particularly the presence of massive apatite veins) similar to those observed in the Mountain Zone. Several intervals exceeding 50 m with grades above 10% P₂O₅ were intersected within the broader composite intervals.
The Southern Zone highlights high-grade phosphate occurring in down-dip continuity, displaying mineralogical and visual characteristics comparable to those recognized in the Mountain Zone. Several intervals exceeding 50 m with grades above 6% P₂O₅ were intersected within the broader composite intervals.
Please note that the intersections reported in this news release represent drilled core lengths. True widths are estimated to be greater than 70%.
Sampling, QA/QC and Analytical Methodology
All drill holes were completed using NQ-size diamond drilling. Drill core was logged, photographed, and sampled according to geological boundaries defined by the Laurentia Exploration technical team. Samples were shipped to Activation Laboratories in Ancaster, Ontario, an independent accredited laboratory, for preparation and analysis using methods appropriate for phosphate. The quality assurance and quality control program includes the regular insertion of in-house reference materials, blanks, and duplicates, in accordance with industry best practices.
Qualified Person
The scientific and technical information relating to First Phosphate contained in this press release has been reviewed and approved by Steeve Lavoie, P.Geo., Chief Geologist of First Phosphate, who is Qualified Person within the meaning of National Instrument 43-101 – Standards of Disclosure for Mineral Projects (“NI 43-101”).
About First Phosphate Corp.
First Phosphate (CSE: PHOS) (OTCQX: FRSPF) (OTCQX ADR: FPHOY) (FSE: KD0) is a mineral exploration and development and clean technology company dedicated to building and reshoring a vertically integrated mine-to-market supply chain for the production of LFP batteries in North America. Target markets include energy storage, data centers, robotics, mobility, and national security.
First Phosphate’s flagship Bégin-Lamarche property, located in Saguenay-Lac-Saint-Jean, Québec, Canada, represents a rare North American igneous phosphate resource producing high-purity phosphate characterized by very low levels of impurities.
Forward-Looking Information and Cautionary Statement
This release includes certain statements that may be deemed “forward-looking information”. Any statement that discusses predictions, expectations, beliefs, plans, projections, objectives, assumptions, future events or performance (often but not always using phrases such as “expects”, or “does not expect”, “is expected”, “anticipates” or “does not anticipate”, “plans”, “budget”, “scheduled”, “forecasts”, “estimates”, “believes” or “intends” or variations of such words and phrases or stating that certain actions, events or results “may” or “could”, “would”, “might” or “will” be taken to occur or be achieved) are not statements of historical fact and may be forward-looking information. In particular, this press release contains forward-looking information relating to, among other things: the Company’s planned exploration and production activities; the timing and completion of geological modelling deliverables and their consistency with the disclosure contained herein; the properties and composition of any extracted phosphate and other minerals; and the Company’s plans for vertical integration into North American supply chains. Although the Company believes the expectations expressed in such forward-looking statements are based on reasonable assumptions, such statements are not guarantees of future performance and actual results or developments may differ materially from those forward-looking statements. Factors that could cause actual results to differ materially from those in forward-looking statements include development and exploration successes, continued availability of capital and financing, and general economic, market or business conditions. These statements are based on a number of assumptions including, among other things: that engineering and construction timetables and capital costs for the Company’s, exploration, development and expansion projects are correctly estimated and not affected by unforeseen circumstances; the ability to obtain financing for its proposed operations on acceptable terms; no material deterioration in general business and economic conditions; no material delays in obtaining permits and other approvals; no significant disruptions affecting the activities of the Company or its ability to access required project equipment and services, and operating supplies in sufficient quantities and on a timely basis; inflation and prices for Company project inputs being approximately consistent with anticipated levels; the ability to complete the exploration and development programs consistent with the Company’s expectations; commodity price expectations including assumptions for P205; the Company’s relationship with local municipalities and First Nations remaining consistent with the Company’s expectations; the Company’s relationship with other third party partners and suppliers remaining consistent with the Company’s expectations; and government relations and actions being consistent with Company expectations. Investors are cautioned that any such statements are not guarantees of future performance and actual results or developments may differ materially from those projected in the forward-looking statements. Accordingly, readers should not place undue reliance on the forward-looking information contained in this press release. The Company does not assume any obligation to update or revise its forward-looking statements, whether because of new information, future events or otherwise, except as required by applicable law. All forward-looking information contained in this release is qualified by these cautionary statements.
SAN DIEGO, April 27, 2026 (GLOBE NEWSWIRE) — Cardiff Oncology, Inc. (Nasdaq: CRDF), a clinical-stage biotechnology company leveraging PLK1 inhibition to develop novel therapies across a range of cancers, today announced that the Company will host a key opinion leader (KOL) webinar to discuss data from an investigator-initiated trial on onvansertib’s single-agent clinical activity in chronic myelomonocytic leukemia (CMML). The webinar will take place on Thursday, April 30th, 2026, at 11:00 a.m. ET.
The webinar will feature KOL Mrinal Patnaik, MBBS, a physician scientist with the Division of Hematology, Department of Internal Medicine at Mayo Clinic, Minnesota. He is the Chair of the Acute Leukemia and Myeloid Neoplasms group at Mayo Clinic, Rochester and is also the Scientific Director of the Epigenetics Developmental Laboratory and the Epigenomics Program. His main clinical and research interests lie in precision genomics and epigenetics and the application of the same to myeloid neoplasms and bone marrow failure syndromes. He directs the Mayo Clinic Clonal hematopoiesis Clinic (CHIP), bone marrow failure syndrome clinic and the short telomere clinic.
KOL Webinar Information
Interested parties can register for and access the live webcast by visiting the “Events” section of the Cardiff Oncology website. The webcast replay will be available after the conclusion of the discussion.
About CardiffOncology, Inc. Cardiff Oncology is a clinical-stage biotechnology company advancing innovative cancer treatments focused on PLK1 inhibition, a validated oncology target with practice-changing potential. Our lead asset, onvansertib, is a highly specific, oral PLK1 inhibitor currently being evaluated in a Phase 2 trial for first-line treatment of RAS-mutated metastatic colorectal cancer (“mCRC”), addressing a large, underserved patient population with high unmet need. Onvansertib is also under investigation in other PLK1-driven cancers through ongoing investigator-initiated trials and has shown robust single agent clinical activity in hard-to-treat tumors. By targeting tumor vulnerabilities, we aim to overcome treatment resistance and deliver improved clinical outcomes for patients.
Total revenue of $516.0 million, net income of $9.1 million, and Adjusted EBITDA of $155.0 million
2026 expected coal sales volumes over 95% committed and priced at the midpoint of 2026 guidance
Record oil & gas royalty revenues and volumes, up 14.6% and 16.1%, respectively, year-over-year
Completed $16.2 million in oil & gas mineral interest acquisitions during the 2026 Quarter
Total and net leverage ratios as of March 31, 2026, were 0.73 times and 0.69 times, respectively
Declares quarterly cash distribution of $0.60 per unit, or $2.40 per unit annualized
TULSA, Okla.–(BUSINESS WIRE)–Alliance Resource Partners, L.P. (NASDAQ: ARLP) (“ARLP” or the “Partnership”) today reported financial and operating results for the quarter ended March 31, 2026 (the “2026 Quarter”). This release includes comparisons of results to the quarter ended March 31, 2025 (the “2025 Quarter”) and to the quarter ended December 31, 2025 (the “Sequential Quarter”). All references in the text of this release to “net income” refer to “net income attributable to ARLP.” For a definition of Adjusted EBITDA and Segment Adjusted EBITDA Expense and related reconciliations to comparable GAAP financial measures, please see the end of this release.
Total revenues decreased 4.5% to $516.0 million for the 2026 Quarter compared to $540.5 million for the 2025 Quarter primarily due to lower coal sales pricing, partially offset by record oil & gas royalty revenues and higher coal sales volumes. Net income for the 2026 Quarter was $9.1 million, or $0.07 per basic and diluted limited partner unit, compared to $74.0 million, or $0.57 per basic and diluted limited partner unit, for the 2025 Quarter. Net income was impacted by lower coal sales and higher depreciation, as well as an $11.6 million decrease in the fair value of our digital assets and a $37.8 million non-cash asset impairment charge in the 2026 Quarter due to ceasing longwall production and uncertainty regarding future operations at our Mettiki mine. Adjusted EBITDA decreased 3.1% to $155.0 million in the 2026 Quarter compared to $159.9 million in the 2025 Quarter.
Compared to the Sequential Quarter, total revenues decreased by 3.6% due to lower coal sales volumes and prices, partially offset by higher oil & gas royalty revenues. Net income decreased by 89.0% compared to the Sequential Quarter primarily due to lower production and lower coal sales volumes from our Hamilton mine as a result of a planned extended longwall move during the 2026 Quarter that led to higher per ton operating expenses. In addition, increased depreciation, non-cash asset impairment charges at Mettiki and lower investment income contributed to lower net income in the 2026 Quarter. Adjusted EBITDA for the 2026 Quarter decreased by 18.9% compared to the Sequential Quarter primarily due to higher costs at Hamilton and Mettiki.
CEO Commentary
“Most of our coal operations performed better than expected during the quarter, however meaningful weather-related shipment disruptions relating to Winter Storm Fern delayed sales volumes for the quarter,” said Joseph W. Craft III, Chairman, President and Chief Executive Officer. “In the Illinois Basin, increased productivity at River View and Gibson South helped offset some of the impact of the planned extended longwall move at Hamilton. In Appalachia, Tunnel Ridge had production gains of approximately 28% compared to both the 2025 Quarter and the Sequential Quarter, while results at Mettiki reflected lower production and a non-cash impairment associated with ceasing longwall production and uncertainty regarding future operations as previously discussed.”
Mr. Craft added, “We delivered another record quarter in our oil & gas royalties segment, driven by increased production volumes and higher oil prices. Increased drilling and completion activity across our core basins continues to validate the quality of our mineral portfolio, and for the second consecutive quarter, we expanded our portfolio, completing $16.2 million in acquisitions during the quarter. These results underscore the durability of our asset base and reinforce our disciplined approach to allocating capital to attractive, long-lived mineral interests. We believe our oil and gas royalties portfolio enhances our cash flow stability and long-term optionality across commodity cycles.”
Coal Operations
Coal sales volumes decreased by 5.9% in the Illinois Basin compared to the Sequential Quarter due primarily to decreased tons sold from our Hamilton mine as a result of a planned extended longwall move during the 2026 Quarter. In Appalachia, tons sold increased by 3.6% and 8.0% compared to the 2025 Quarter and Sequential Quarter, respectively, primarily as a result of fewer production days in the prior periods at our Tunnel Ridge mine due to longwall moves. Coal sales price per ton sold decreased by 7.4% in the Illinois Basin compared to the 2025 Quarter as a result of the expiration of higher priced legacy contracts. In Appalachia, coal sales price per ton sold decreased by 4.8% and 11.1% compared to the 2025 Quarter and Sequential Quarter, respectively, primarily due to an increased sales mix of lower priced Tunnel Ridge sales volumes in the 2026 Quarter and reduced domestic sales price per ton. ARLP ended the 2026 Quarter with total coal inventory of 1.2 million tons, representing a decrease of 0.2 million tons and an increase of 0.1 million tons compared to the end of the 2025 Quarter and Sequential Quarter, respectively.
Segment Adjusted EBITDA Expense per ton in the Illinois Basin increased 3.4% compared to the Sequential Quarter due primarily to the planned extended longwall move at our Hamilton mine during the 2026 Quarter. In Appalachia, Segment Adjusted EBITDA Expense per ton for the 2026 Quarter decreased by 10.8% compared to the 2025 Quarter as a result of increased production at our Tunnel Ridge operation primarily as a result of fewer production days due to the longwall moves in the 2025 Quarter.
Royalties
Segment Adjusted EBITDA for the Oil & Gas Royalties segment increased to $34.6 million in the 2026 Quarter compared to $29.9 million and $30.0 million in the 2025 Quarter and Sequential Quarter, respectively, due to record oil & gas royalty volumes, which increased 16.1% and 3.3%, respectively, as a result of increased drilling and completion activities on our interests and acquisitions of additional oil & gas mineral interests. Improved commodity pricing also contributed to the increase in Segment Adjusted EBITDA compared to the Sequential Quarter.
Segment Adjusted EBITDA for the Coal Royalties segment increased to $12.3 million in the 2026 Quarter compared to $9.4 million in the 2025 Quarter due to higher royalty tons sold, primarily from Tunnel Ridge, partially offset by lower average royalty rates per ton received from the Partnership’s mining subsidiaries. Compared to the Sequential Quarter, Segment Adjusted EBITDA for the Coal Royalties segment decreased 15.7%, primarily reflecting lower realized royalty rates per ton.
Balance Sheet and Liquidity
As of March 31, 2026, total debt and finance leases were outstanding in the amount of $507.7 million. The Partnership’s total and net leverage ratios were 0.73 times and 0.69 times debt to trailing twelve months Adjusted EBITDA, respectively, as of March 31, 2026. ARLP ended the 2026 Quarter with total liquidity of $431.2 million, which included $28.9 million of cash and cash equivalents and $402.3 million of borrowings available under its revolving credit and accounts receivable securitization facilities. In addition, ARLP held 618 bitcoins valued at $42.2 million as of March 31, 2026.
Distributions
ARLP announced today that the Board of Directors of ARLP’s general partner approved a cash distribution to unitholders for the 2026 Quarter of $0.60 per unit (an annualized rate of $2.40 per unit), payable on May 15, 2026, to all unitholders of record as of the close of trading on May 8, 2026.
Concurrent with this announcement we are providing qualified notice to brokers and nominees that hold ARLP units on behalf of non-U.S. investors under Treasury Regulation Section 1.1446-4(b) and (d) and Treasury Regulation Section 1.1446(f)-4(c)(2)(iii). Brokers and nominees should treat one hundred percent (100%) of ARLP’s distributions to non-U.S. investors as being attributable to income that is effectively connected with a United States trade or business. In addition, brokers and nominees should treat one hundred percent (100%) of the distribution as being in excess of cumulative net income for purposes of determining the amount to withhold. Accordingly, ARLP’s distributions to non-U.S. investors are subject to federal income tax withholding at a rate equal to the highest applicable effective tax rate plus ten percent (10%). Nominees, and not ARLP, are treated as the withholding agents responsible for withholding on the distributions received by them on behalf of non-U.S. investors.
Outlook
“Looking ahead, contracting activity with domestic utility customers for 2026 has remained active, though the pace has varied as some customers continue to evaluate summer burn requirements,” commented Mr. Craft. “During the quarter, the Iran conflict briefly reopened U.S. thermal coal export activity in early March, enabling us to enter into contracts for 1.8 million tons to be delivered in 2026 and 2027. In addition, we sold an additional 0.5 million tons to domestic customers, bringing our sales book to more than 95% committed and priced for 2026 assuming production comes in at the midpoint of our guidance range. Our remaining open position is concentrated in the second half of 2026, where additional commitments will depend on summer burn and customer requirements. More broadly, we continue to see a constructive demand backdrop as growing power demand, particularly from data centers, reinforces the importance of reliable baseload generation.”
Mr. Craft continued, “We expect first quarter shipment disruptions tied to Winter Storm Fern and subsequent high-water conditions to be recovered over the balance of the year. In addition, once the planned longwall moves at Hamilton and Tunnel Ridge are completed in the second quarter, we do not expect any further longwall moves in 2026, which should improve operating visibility for the back half of the year.”
Mr. Craft concluded, “Based on year-to-date outperformance of our oil & gas royalties, we are increasing our volume guidance for the segment. Recent strength and volatility in crude oil prices have increased the near-term outlook and, because our current portfolio is unhedged, changes in market prices are reflected directly in our realized pricing. If current market conditions persist, we would expect realized BOE prices to be higher than last year, contributing to stronger segment results.”
ARLP is updating the following guidance for the full year ending December 31, 2026:
Conference Call
A conference call regarding ARLP’s 2026 Quarter financial results and updated 2026 guidance is scheduled for today at 10:00 a.m. Eastern. To participate in the conference call, dial (877) 407-0784 and request to be connected to the Alliance Resource Partners, L.P. earnings conference call. International callers should dial (201) 689-8560 and request to be connected to the same call. Investors may also listen to the call via the “Investors” section of ARLP’s website at www.arlp.com.
An audio replay of the conference call will be available for approximately one week. To access the audio replay, dial U.S. Toll Free (844) 512-2921; International Toll (412) 317-6671 and request to be connected to replay using access code 13759702.
About Alliance Resource Partners, L.P.
ARLP is a diversified natural resource company that is currently the second largest coal producer in the eastern United States, supplying reliable, affordable energy domestically and internationally to major utilities, metallurgical and industrial users. ARLP also generates operating and royalty income from mineral interests it owns in strategic coal and oil & gas producing regions in the United States. In addition, ARLP is positioning itself as a reliable energy partner for the future by pursuing opportunities that support the growth and development of energy-related technologies and infrastructure.
News, unit prices and additional information about ARLP, including filings with the Securities and Exchange Commission (“SEC”), are available at www.arlp.com. For more information, contact the investor relations department of ARLP at (918) 295-7673 or via e-mail at [email protected].
The statements and projections used throughout this release are based on current expectations. These statements and projections are forward-looking, and actual results may differ materially. These projections do not include the potential impact of any mergers, acquisitions or other business combinations that may occur after the date of this release. We have included more information below regarding business risks that could affect our results.
Robert LeBoyer, Senior Vice President, Equity Research Analyst, Biotechnology, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
We Believe The Proposal Is Misunderstood. On April 20, Ocugen filed its proxy statement and Annual Meeting Notice. In addition to the usual business and shareholder matters, there is a proposal to authorize a reverse split. We believe the reverse split could lift the stock to a trading range that meets minimum share price requirements for ownership by more index funds, institutions, and investors.
The Reverse Split Could Open The Stock To More Investors. Ocugen’s three lead clinical programs have reported data that have driven an increase in its market valuation to about $550 to $600 million. However, many index funds, institutions, and brokerage firms have requirements for both minimum share price and market valuation before they can own the stock. We believe the reverse split would help meet these requirements sooner and open the stock to new investors. We expect the stream of clinical milestones in the coming year to sustain the post-split price and drive it higher.
Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.
Mark Reichman, Managing Director, Equity Research Analyst, Natural Resources, Noble Capital Markets, Inc.
Refer to the full report for the price target, fundamental analysis, and rating.
Significant progress in 2025. Kuya reported its financial and operational results for the fourth quarter and FY 2025, while also announcing key leadership appointments to strengthen its operations in Peru. Edgardo Orderique was named General Manager for Peru, bringing senior-level experience from major mining operations, and will oversee mining and processing at the Bethania Silver Project. He is supported by Jesus Palomino as Operations Manager and German Minaya as Finance and Administration Manager. These additions are intended to enhance execution as the company transitions from early-stage production to scaled operations with higher throughput.
Operational momentum. The company made steady progress, achieving record processing volumes and improved production consistency. Production reached approximately 100 tonnes per day in March, with a target of 350 tonnes per day by the end of 2026 under its Phase One expansion plan. This growth is supported by investments in underground development, infrastructure, and workforce training, along with modernization efforts to improve efficiency. Kuya increased its exploration program to 20,000 meters of drilling in 2026.
Equity Research is available at no cost to Registered users of Channelchek. Not a Member? Click ‘Join’ to join the Channelchek Community. There is no cost to register, and we never collect credit card information.
This Company Sponsored Research is provided by Noble Capital Markets, Inc., a FINRA and S.E.C. registered broker-dealer (B/D).
*Analyst certification and important disclosures included in the full report. NOTE: investment decisions should not be based upon the content of this research summary. Proper due diligence is required before making any investment decision.
